JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
130.43
+0.93 (+0.72%)
At close: 4:00PM EDT

130.43 0.00 (0.00%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close129.50
Open129.75
Bid130.33 x 1200
Ask130.80 x 900
Day's Range128.93 - 130.74
52 Week Range118.62 - 148.32
Volume5,337,586
Avg. Volume6,428,954
Market Cap349.912B
Beta0.60
PE Ratio (TTM)259.30
EPS (TTM)0.50
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.74%)
Ex-Dividend Date2018-08-27
1y Target Est143.35
Trade prices are not sourced from all markets
  • A Performance Overview of Bausch + Lomb
    Market Realist4 hours ago

    A Performance Overview of Bausch + Lomb

    Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter compared to $1.22 billion in the second quarter of 2017, reflecting a ~1% YoY (year-over-year) fall. However, Bausch + Lomb witnessed ~4% YoY organic growth in the second quarter.

  • A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity
    Bloomberg5 hours ago

    A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity

    People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.

  • SurveyMonkey adds Emory dean to board of directors, balancing its gender representation
    American City Business Journalsyesterday

    SurveyMonkey adds Emory dean to board of directors, balancing its gender representation

    Erika Hayes James became the first African-American woman appointed dean of a top-25 business school when she was tapped for the role at the John H. Harland Dean of Goizueta Business School in 2014.

  • Better Buy: AbbVie Inc. vs. Johnson & Johnson
    Motley Foolyesterday

    Better Buy: AbbVie Inc. vs. Johnson & Johnson

    Which stock wins in a match-up between these two big pharma companies?

  • InvestorPlace2 days ago

    The Philosophy of Dividend Aristocrat Stocks

    One popular form of dividend investing involves a group of stocks called dividend aristocrats. Standards of what makes up a dividend aristocrat vary. Of the thousands of stocks that trade on American exchanges, only 53 stocks currently hold dividend aristocrat status.

  • TheStreet.com2 days ago

    Buy Johnson & Johnson, Now Poised to Rally

    In this daily bar chart of JNJ, below, we can see that JNJ has been testing the declining 200-day moving average line. The daily On-Balance-Volume (OBV) line has been going up since early June and it is close to making a new high above the April peak. A rising OBV line is a sign that buyers of a stock are being more aggressive.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks2 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool2 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.

  • See what the IHS Markit Score report has to say about Johnson & Johnson.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    Johnson & Johnson NYSE:JNJ

  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • 3 Reasons Cisco Systems Stock Can Surge to $50
    InvestorPlace5 days ago

    3 Reasons Cisco Systems Stock Can Surge to $50

    Like many tech stocks, Cisco Systems (NASDAQ:CSCO) has declined in recent days. Now that the shares are roughly 7.5% off the highs reached in May, is it time to pull the trigger and buy Cisco? For those interested in the name, here are three catalysts that can push Cisco higher.

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks5 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Reuters6 days ago

    Factbox: U.S. companies with exposure to Russia

    The United States on Wednesday announced it would impose fresh sanctions on Russia after Washington determined Moscow had used a nerve agent against a former Russian double agent, Sergei Skripal, and his daughter, Yulia, in Britain. Russia on Thursday condemned the new round of sanctions as illegal and said it had begun working on retaliatory measures.

  • Generic Drugmakers Struggle Despite U.S. Push for Copycats
    Bloomberg6 days ago

    Generic Drugmakers Struggle Despite U.S. Push for Copycats

    Generic drugmakers are being crushed by the very forces that the Trump administration is counting on to drive down prescription costs. While policy makers are betting that opening the market to a deluge of new medicines and reforming the drug supply chain will help contain rising prices, many widely used copycat medications are already seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water. As a result, companies including Mylan NV and Perrigo Co. are being forced to consider shakeups.

  • Examining Pfizer’s Valuation as of August 6
    Market Realist6 days ago

    Examining Pfizer’s Valuation as of August 6

    Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.

  • Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations
    PR Newswire7 days ago

    Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations

    Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business. Mr. DelOrefice holds a Bachelor of Science and MBA from Villanova University, and received his CPA certification from the Commonwealth of PA.

  • These Products Saw Falling Sales in Pfizer’s Q2 2018
    Market Realist7 days ago

    These Products Saw Falling Sales in Pfizer’s Q2 2018

    Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market. These products include Enbrel (outside the United States and Canada), Sutent, Xalkori, BeneFix, Premarin Family, Medrol, Celebrex, Lyrica, and Viagra.

  • Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
    PR Newswire8 days ago

    Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference

    NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Boston ...

  • Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference
    PR Newswire8 days ago

    Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference

    NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston ...

  • Pfizer’s Quarterly Revenue Trend in Q2 2018
    Market Realist8 days ago

    Pfizer’s Quarterly Revenue Trend in Q2 2018

    Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health. As we discussed in the previous article, Pfizer reported a YoY (year-over-year) rise of 4% in its top line to $13.5 billion in the second quarter compared to $12.9 million during the second quarter of 2017. This outperformance was driven by a 2% favorable foreign exchange impact and a 2% rise in operating revenue in the second quarter.

  • Reuters8 days ago

    Trump seeks out business leaders as midterm election looms

    U.S. President Donald Trump will dine with some of corporate America's top business leaders at his private club on Tuesday, seeking their thoughts on the nation's economy as voters begin heading to the polls ahead of November's midterm election. Trump is hosting the chief executives for dinner at his golf resort in Bedminster, New Jersey. Expected attendees include the heads of Fiat Chrysler Automobiles NV, Boeing Co , FedEx Corp, and Honeywell International Inc , White House Deputy Press Secretary Lindsay Walters said.

  • Q2 Earnings Drive Pharma ETFs Higher
    Zacks8 days ago

    Q2 Earnings Drive Pharma ETFs Higher

    The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.

  • See what the IHS Markit Score report has to say about Johnson & Johnson.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    Johnson & Johnson NYSE:JNJ

  • Jury orders Monsanto to pay $289 million in Roundup cance...
    CNBC Videos2 days ago

    Jury orders Monsanto to pay $289 million in Roundup cance...

    CNBC's Aditi Roy reports on the lawsuit against Monsanto over its allegedly carcinogenic herbicide, Roundup.

  • NYSE trader: Stocks could drop in August
    Yahoo Finance Video7 days ago

    NYSE trader: Stocks could drop in August

    Alan Valdes of Silverbear Capital joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves. Here's the performance of select trending stocks as of 3:00 pm ET: CGC(HB) Canopy Growth 4.03% CVS CVS Health Corp 3.69% GEVO(HB) Gevo Inc 2.58% BB(HB) BlackBerry Ltd 2.44% FIT Fitbit Inc 2.25% ACBFF(HB) Aurora Cannabis Inc 2.13% ARWR(0) Arrowhead Pharma Inc 1.46% LRCX Lam Research 1.19% PFE Pfizer Inc 0.95% GOOGL Alphabet Inc Cl A 0.94% NVDA Nvidia Corp 0.92% AMZN Amazon.com Inc 0.89% SIRI Sirius XM Hldgs Inc 0.80% GOOG Alphabet Inc Cl C Cap Stock 0.88% BILI(HB) Bilibili Inc ADS 0.79% C Citigrp Inc 0.70% BAC Bank of America Corporation 0.67% FB Facebook Inc 0.61% AMAT Applied Materials 0.42% CRM salesforce.com Inc 0.43% JCP(HB) Penney (J.C.) 0.42% JPM JPMorgan Chase & Co 0.37% WFC Wells Fargo 0.34% HD Home Depot Inc 0.31% VZ Verizon Communications 0.29% T AT&T Inc 0.29% SHOP Shopify Inc 0.29% PBR Petroleo Brasileiro S.A. ADS 0.16% HMNY(HB,F) Helios and Matheson Analytics 0.14% MSFT Microsoft Corp 0.14% ADBE Adobe Systems 0.12% AVGO Broadcom Inc 0.06% PYPL PayPal Hldgs Inc 0.08% AAPL Apple Inc 0.01% QQQ Invesco QQQ Trust Series 1 0.02% KMI Kinder Morgan Inc -0.03% CSCO Cisco Systems -0.02% CELG Celgene Corp -0.02% ORCL Oracle Corp -0.08% ABBV AbbVie Inc -0.11% V Visa Inc -0.06% SPY SPDR S&P 500 ETF -0.14% QCOM Qualcomm Inc -0.15% INTC Intel Corp -0.17% MU Micron Tech -0.14% F Ford Motor -0.20% TVIX(HB) VS 2X VIX Short Term -0.19% NKTR(0) Nektar Therapeutics -0.27% JNJ Johnson & Johnson -0.30% PG Procter & Gamble Cc -0.35% WMT Wal-Mart Stores -0.37% BP BP P.L.C. ADS -0.38% NKE Nike Inc Cl B -0.41% IBM Intl Business Machines Corp -0.43% SQ Square Inc -0.42% KO Coca-Cola Co -0.43% VXX iPath S&P 500 VIX Short-Term -0.42% AMD Advanced Micro Devices Inc -0.49% UVXY ProShs Ultra VIX Short-Term -0.25% NFLX Netflix Inc -0.47% SDRL(HB) Seadrill Limited -0.50% BIDU Baidu Inc -0.62% BA Boeing Co -0.64% CVX Chevron Corporation -0.80% XOM Exxon Mobil -0.81% JD JD.com Inc -0.88% BABA Alibaba Group Holding Ltd -0.92% GE General Electric Co -0.99% GILD Gilead Sciences -1.00% CMCSA(HB) Comcast Cl A -1.09% SRPT Sarepta Therapeutics Inc -1.12% SBUX Starbucks Corp -1.23% TSLA(HB) Tesla Inc -1.17% CHK Chesapeake Energy Corp -1.28% WBA Walgreen Boots Alliance Inc -1.29% TWTR Twitter Inc -1.32% SOGO(HB) Sogou Inc -1.40% CAT Caterpillar Inc -1.40% MO Altria Grp -1.58% TEVA Teva Pharm Indus ADR -1.70% DBX Dropbox Inc -1.82% IQ IQIYI Inc ADS -2.01% RAD Rite Aid -2.33% DIS Disney (Walt) Co -2.06% ROKU Roku Inc Cl A -2.24% HUYA(HB) HUYA Inc -2.62% GERN(HB) Geron Corp -2.44% X U.S. Steel Corporation -2.59% SNAP(HB) Snap Inc -6.02% TRXC(HB) TransEnterix Inc -7.98%